Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free VTVT Stock Alerts

vTv Therapeutics (VTVT) Competitors

vTv Therapeutics logo
$32.94 -0.06 (-0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$32.97 +0.03 (+0.08%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VTVT vs. AVTE, EIKN, FDMT, PRTA, and AQST

Should you buy vTv Therapeutics stock or one of its competitors? MarketBeat compares vTv Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with vTv Therapeutics include Aerovate Therapeutics (AVTE), Eikon Therapeutics (EIKN), 4D Molecular Therapeutics (FDMT), Prothena (PRTA), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

How does vTv Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, vTv Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Aerovate Therapeutics. vTv Therapeutics' average media sentiment score of 0.94 beat Aerovate Therapeutics' score of 0.67 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Positive
vTv Therapeutics Positive

vTv Therapeutics has a consensus price target of $53.00, indicating a potential upside of 60.90%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

vTv Therapeutics' return on equity of 3.96% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
vTv Therapeutics N/A 3.96%2.86%

17.5% of vTv Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

vTv Therapeutics has higher revenue and earnings than Aerovate Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
vTv Therapeutics$1.02M127.24-$26.97M-$0.93N/A

Summary

vTv Therapeutics beats Aerovate Therapeutics on 12 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Eikon Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

vTv Therapeutics' return on equity of 3.96% beat Eikon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A 3.96% 2.86%
Eikon Therapeutics N/A N/A N/A

17.5% of vTv Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

vTv Therapeutics presently has a consensus target price of $53.00, suggesting a potential upside of 60.90%. Eikon Therapeutics has a consensus target price of $25.20, suggesting a potential upside of 167.23%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

Eikon Therapeutics has lower revenue, but higher earnings than vTv Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M127.24-$26.97M-$0.93N/A
Eikon TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Eikon Therapeutics had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.94 beat Eikon Therapeutics' score of 0.69 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eikon Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

vTv Therapeutics beats Eikon Therapeutics on 8 of the 10 factors compared between the two stocks.

How does vTv Therapeutics compare to 4D Molecular Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.94 beat 4D Molecular Therapeutics' score of 0.54 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
4D Molecular Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

vTv Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M127.24-$26.97M-$0.93N/A
4D Molecular Therapeutics$85.21M5.85-$140.11M-$2.57N/A

vTv Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. vTv Therapeutics' return on equity of 3.96% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A 3.96% 2.86%
4D Molecular Therapeutics -182.34%-36.83%-32.55%

vTv Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

vTv Therapeutics currently has a consensus target price of $53.00, indicating a potential upside of 60.90%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 213.48%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
4D Molecular Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

vTv Therapeutics beats 4D Molecular Therapeutics on 9 of the 17 factors compared between the two stocks.

How does vTv Therapeutics compare to Prothena?

vTv Therapeutics (NASDAQ:VTVT) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

vTv Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. vTv Therapeutics' return on equity of 3.96% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A 3.96% 2.86%
Prothena -260.92%-43.44%-36.87%

vTv Therapeutics has higher earnings, but lower revenue than Prothena. vTv Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M127.24-$26.97M-$0.93N/A
Prothena$57.94M8.06-$244.09M-$2.82N/A

vTv Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

vTv Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 60.90%. Prothena has a consensus price target of $23.75, suggesting a potential upside of 166.26%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Prothena
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.63

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, vTv Therapeutics and vTv Therapeutics both had 2 articles in the media. Prothena's average media sentiment score of 1.62 beat vTv Therapeutics' score of 0.94 indicating that Prothena is being referred to more favorably in the news media.

Company Overall Sentiment
vTv Therapeutics Positive
Prothena Very Positive

Summary

vTv Therapeutics beats Prothena on 9 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Aquestive Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

vTv Therapeutics presently has a consensus target price of $53.00, indicating a potential upside of 60.90%. Aquestive Therapeutics has a consensus target price of $8.80, indicating a potential upside of 118.36%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

vTv Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M127.24-$26.97M-$0.93N/A
Aquestive Therapeutics$44.54M11.35-$83.78M-$0.61N/A

vTv Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. vTv Therapeutics' return on equity of 3.96% beat Aquestive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A 3.96% 2.86%
Aquestive Therapeutics -137.08%N/A -49.33%

vTv Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

In the previous week, vTv Therapeutics had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.89 beat vTv Therapeutics' score of 0.94 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
vTv Therapeutics Positive
Aquestive Therapeutics Very Positive

Summary

Aquestive Therapeutics beats vTv Therapeutics on 10 of the 16 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTVT vs. The Competition

Export
MetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$129.78M$3.28B$6.25B$12.42B
Dividend YieldN/A2.33%2.69%5.29%
P/E Ratio-35.4217.9322.3024.19
Price / Sales127.24324.62581.37138.33
Price / CashN/A116.2742.3157.88
Price / Book2.016.639.846.72
Net Income-$26.97M$24.20M$3.57B$337.19M
7 Day Performance-2.31%-3.25%-1.16%0.48%
1 Month Performance3.98%0.53%3.85%5.06%
1 Year Performance102.09%47.24%27.40%34.27%

vTv Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTVT
vTv Therapeutics
3.1061 of 5 stars		$32.94
-0.2%		$53.00
+60.9%		+95.2%$129.78M$1.02MN/A9
AVTE
Aerovate Therapeutics
N/A$18.59
-11.6%		N/A+156.4%$538.83MN/AN/A20
EIKN
Eikon Therapeutics
N/A$9.60
-11.0%		$25.20
+162.5%		N/A$519.73MN/AN/A384
FDMT
4D Molecular Therapeutics
2.2435 of 5 stars		$9.27
-4.5%		$29.88
+222.3%		+147.2%$507.60M$85.21MN/A120
PRTA
Prothena
2.9213 of 5 stars		$9.19
-4.2%		$23.75
+158.4%		+97.2%$502.07M$9.68MN/A130

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel